Corporate Overview Presentation Wednesday, September 11, 2013 at 4:25pm ET
NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that Martin Shkreli, Founder, President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference 2013 on Wednesday, September 11, 2013 at 4:25pm ET at the Four Seasons Hotel in Boston, MA. A live webcast and 30-day archive of the Retrophin presentation can be accessed at http://www.veracast.com/webcasts/stifel/healthcare2013/68114573143.cfm. The webcast will also be available on the Company's website, www.retrophin.com, in the Investors/Events & Presentations section.
About Retrophin
Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during 2013. For additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Retrophin, Inc.
Marc Panoff, CFO
(917) 261-3684
marc@retrophin.com
or
Rx Communications Group
Paula Schwartz (Investors)
(917) 322-2216
pschwartz@rxir.com
Source: Retrophin, Inc.
News Provided by Acquire Media